Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;152(6):541-552.
doi: 10.4103/ijmr.IJMR_1450_18.

Therapeutic uses of post-partum tissue-derived mesenchymal stromal cell secretome

Vindya Lankika Udalamaththa  1 , Athula Kaluarachchi  2 , Sumedha Wijeratne  3 , Preethi Vidya Udagama  1
Affiliations
Review

Therapeutic uses of post-partum tissue-derived mesenchymal stromal cell secretome

Vindya Lankika Udalamaththa et al. Indian J Med Res. 2020 Dec.

Abstract

Human post-partum tissue mesenchymal stromal cells (hPPT-MSCs) are widely used in research to investigate their differentiation capabilities and therapeutic effects as potential agents in cell-based therapy. This is ascribed to the advantages offered by the use of MSCs isolated from hPPT over other MSC sources. A paradigm shift in related research is evident that focuses on the secretome of the human MSCs (hMSCs), as therapeutic effects of hMSCs are attributed more so to their secreted growth factors, cytokines and chemokines and to the extracellular vesicles (EVs), all of which are components of the hMSC secretome. Positive therapeutic effects of the hPPT-MSC secretome have been demonstrated in diseases related to skin, kidney, heart, nervous system, cartilage and bones, that have aided fast recovery by replacing damaged, non-functional tissues, via differentiating and regenerating cells. Although certain limitations such as short half -life of the secretome components and irregular secreting patterns exist in secretome therapy, these issues are successfully addressed with the use of cutting-edge technologies such as genome editing and recombinant cytokine treatment. If the current limitations can be successfully overcome, the hPPT-MSC secretome including its EVs may be developed into a cost-effective therapeutic agent amenable to be used against a wide range of diseases/disorders.

Keywords: Extracellular vesicles; human mesenchymal stromal cell secretome; post-partum tissue; stem cell therapy.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure
Figure
Human post-partum tissue mesenchymal stromal cells secrete growth factors, chemokines, cytokines and extracellular vesicles which form the components of its secretome. These secretome components manifest different therapeutic effects. List of advantages and disadvantages of the therapeutic use of human post-partum tissue mesenchymal stromal cell secretome over current cell therapy methods is provided.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Strauer BE, Kornowski R. Stem cell therapy in perspective. Circulation. 2003;107:929–34. - PubMed
    1. Lv YT, Zhang Y, Liu M, Qiuwaxi JN, Ashwood P, Cho SC, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med. 2013;11:196. - PMC - PubMed
    1. Rajput BS, Chakrabarti SK, Dongare VS, Ramirez CM, Deb KD. Human umbilical cord mesenchymal stem cells in the treatment of duchenne muscular dystrophy: Safety and feasibility study in India. J Stem Cells. 2015;10:141–56. - PubMed
    1. Squillaro T, Peluso G, Galderisi U. Clinical Trials with mesenchymal stem cells: An Update. Cell Transplant. 2016;25:829–48. - PubMed
    1. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res. 2008;100:133–58. - PubMed